| Abstract: | A series of palladium(II) complexes of general formula [Pd(LH+)Cl3] (1–12) containing 6-benzylaminopurine derivatives has been prepared [L?=?6-(2-methoxybenzylamino)purine (1), 6-(3-methoxybenzylamino)purine (2), 6-(4-methoxybenzylamino)purine (3), 6-(2-hydroxy-benzylamino)purine (4), 6-(3-hydroxybenzylamino)purine (5), 6-(4-hydroxybenzylamino) purine (6), 6-(2-fluorobenzylamino)purine (7), 6-(3-fluorobenzylamino)purine (8), 6-(4-fluorobenzylamino)purine (9), 6-(2-chlorobenzylamino)purine (10), 6-(3-chlorobenzylamino) purine (11) and 6-(4-chlorobenzylamino)purine (12)]. The compounds have been characterized by elemental analysis, IR, ES+ MS and 1H- and 13C-NMR spectroscopy, and two of them, 6 and 12, also by TG/DSC analyses. The complexes have been screened in vitro against the four human tumour cell lines G-361, HOS, K-562 and MCF7. |
